Literature DB >> 25446334

The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection.

Christopher Weber1, Katja Sliva2, Christine von Rhein3, Beate M Kümmerer4, Barbara S Schnierle5.   

Abstract

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes chikungunya fever and has infected millions of people mainly in developing countries. The associated disease is characterized by rash, high fever and severe arthritis that can persist for years. CHIKV has adapted to Aedes albopictus, which also inhabits temperate regions, including Europe and the United States of America and might cause new, large outbreaks there. No treatment or licensed CHIKV vaccine exists. Epigallocatechin-3-gallate (EGCG), the major component of green tea, has, among other beneficial properties, antiviral activities. Therefore, we examined if EGCG has antiviral activity against CHIKV. EGCG inhibited CHIKV infection in vitro, blocked entry of CHIKV Env-pseudotyped lentiviral vectors and inhibited CHIKV attachment to target cells. Thus EGCG might be used as a lead structure to develop more effective antiviral drugs.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chikungunya virus; EGCG; Green tea

Mesh:

Substances:

Year:  2014        PMID: 25446334     DOI: 10.1016/j.antiviral.2014.11.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  38 in total

1.  Green tea cultivar 'Benifuuki' potentiates split vaccine-induced immunoglobulin A production.

Authors:  Yeong-Seon Won; Motofumi Kumazoe; Kanako Takamatsu; Yuki Shinoda; Saki Sonoda; Kenji Okada; Takehisa Okamoto; Hirofumi Tachibana
Journal:  J Nat Med       Date:  2016-08-03       Impact factor: 2.343

Review 2.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

Review 3.  Towards antivirals against chikungunya virus.

Authors:  Rana Abdelnabi; Johan Neyts; Leen Delang
Journal:  Antiviral Res       Date:  2015-06-25       Impact factor: 5.970

4.  In silico identification and in vitro antiviral validation of potential inhibitors against Chikungunya virus.

Authors:  Jyoti Verma; Abdul Hasan; Sujatha Sunil; Naidu Subbarao
Journal:  J Comput Aided Mol Des       Date:  2022-07-05       Impact factor: 4.179

Review 5.  Prophylactic strategies to control chikungunya virus infection.

Authors:  Friederike I L Hucke; Malena Bestehorn-Willmann; Joachim J Bugert
Journal:  Virus Genes       Date:  2021-02-15       Impact factor: 2.332

Review 6.  Early Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane Fusion.

Authors:  Mareike K S van Duijl-Richter; Tabitha E Hoornweg; Izabela A Rodenhuis-Zybert; Jolanda M Smit
Journal:  Viruses       Date:  2015-07-07       Impact factor: 5.048

Review 7.  Antiviral Activity Exerted by Natural Products against Human Viruses.

Authors:  Maria Musarra-Pizzo; Rosamaria Pennisi; Ichrak Ben-Amor; Giuseppina Mandalari; Maria Teresa Sciortino
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.048

8.  Previously published ethno-pharmacological reports reveal the potentiality of plants and plant-derived products used as traditional home remedies by Bangladeshi COVID-19 patients to combat SARS-CoV-2.

Authors:  A T M Rafiqul Islam; Jannatul Ferdousi; Md Shahinozzaman
Journal:  Saudi J Biol Sci       Date:  2021-07-17       Impact factor: 4.219

Review 9.  Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19.

Authors:  Ying-Qi Wang; Qing-Sheng Li; Xin-Qiang Zheng; Jian-Liang Lu; Yue-Rong Liang
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 10.  Small Molecule Inhibitors Targeting Chikungunya Virus.

Authors:  Nicole Haese; John Powers; Daniel N Streblow
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.